Recently, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics' innovative drug Avlayah (tividenofusp alfa) for the treatment of Hunter syndrome (Mucopolysaccharidosis II). This approval marks a dual breakthrough: it is not only the first new treatment option for this disease in nearly 20 years but also the first FDA-approved enzyme replacement therapy that utilizes a transferrin receptor-mediated mechanism to cross the blood-brain barrier.

Hunter syndrome is a rare genetic lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulfatase (IDS), leading to abnormal accumulation of glycosaminoglycans throughout the body's cells, with particularly severe damage to the central nervous system. While traditional enzyme replacement therapies can improve peripheral symptoms, they cannot effectively cross the blood-brain barrier and therefore fail to halt neurological decline.

The key innovation of Avlayah lies in its TransportVehicle™ (TV) platform technology. This engineered technology enables the drug to bind to transferrin receptors on the blood-brain barrier, facilitating its delivery into the brain. Clinical data show that treatment significantly reduces levels of heparan sulfate in patients' cerebrospinal fluid and helps stabilize or improve cognitive, behavioral, and hearing functions.

Currently, the confirmatory Phase III clinical trial (COMPASS study) for this drug is underway, and its results will determine whether the accelerated approval can be converted to full approval.

https://news.yaozh.com/archive/47630.html